Background. Anal sex is a common sexual behavior among women that increases their risk of acquiring rectal infection with Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC).
Chlamydia, caused by Chlamydia trachomatis (CT), and gonorrhea, caused by Neisseria gonorrhoeae (GC), are the 2 most frequently reported sexually transmitted diseases (STDs) in the United States [1] . In 2015, among 1.5 million chlamydia cases reported to the Centers for Disease Control and Prevention (CDC), 70% were in women; among 0.4 million gonorrhea cases, 45% were in women [1] . Case reports do not include the site of infection, such as genital or rectal, but most of the reported infections were probably genital. Genital chlamydial and gonococcal infections are usually asymptomatic in women, but both symptomatic and asymptomatic infections can lead to pelvic inflammatory disease, ectopic pregnancy, and infertility. CDC and several medical organizations recommend routine annual genital CT and GC screening of sexually active women aged ≤24 years, pregnant women, and older women at increased risk of an STD using nucleic acid amplification testing (NAAT) of a vaginal or endocervical swab specimen or a urine specimen [2] [3] [4] [5] . In addition, CDC recommends that persons who have been treated for chlamydia or gonorrhea at any anatomic site have repeat testing ideally 3 months after treatment but within 12 months of the positive test [2] . Approximately 47.4% of sexually active women aged 16-24 years with commercial managed care insurance were tested for CT in 2015 [6] .
Anal sex is a common sexual behavior reported by women, with 35.9% of women aged 18-44 years reporting ever having anal sex in a national survey [7] . Anal sex is associated with rectal chlamydia and gonorrhea, human immunodeficiency virus (HIV) infection, human papillomavirus (HPV) infection, and anal cancer in women [8] [9] [10] [11] . In both women and men, rectal chlamydia or gonorrhea can serve as biomarkers of risk for HIV acquisition, and these infections can cause mucosal inflammation that increase the risk of HIV infection [12] . Most anal cancer has been attributed to HPV infection, but previous studies have shown that anal sex, history of gonorrhea, partners with a history of an STD, and HIV infection are also risk factors for anal cancer in women [11, 13, 14] . CDC guidelines currently do not recommend rectal CT or GC screening of women who report anal sex [2] .
In this analysis of CT and GC testing data from a large US commercial laboratory, we estimate the frequency and positivity of genital, rectal, and pharyngeal CT and GC tests performed in women. We also describe patterns of follow-up testing among women who had a positive rectal test.
METHODS
We analyzed CT and GC testing data from a large US commercial laboratory that provides testing in all 50 states and the District of Columbia. These data included all CT and GC detection tests performed from 1 November 2012 through 30 September 2015. The database also included information on the patient's age, sex, type of insurance, US geographic region of residence, test type, anatomic site of specimen, test result, diagnostic codes (International Classification of Diseases, Ninth Revision [ICD-9]), and provider specialty. The laboratory system had previously validated NAATs for use with rectal and pharyngeal swab specimens in collaborative studies [15] . Healthcare providers could collect and request testing for CT, GC, or both on a genital, rectal, or pharyngeal specimen, and the laboratory system used unique test numbers to distinguish genital, rectal, and pharyngeal specimens. Among genital tests performed for women, approximately 59% were vaginal or endocervical specimens and 41% were urine specimens. We classified all of these urogenital specimens as "genital" testing. We used a combination of patient characteristics to create a de-identified analytic data set to estimate the number and positivity of CT and GC tests performed for an individual woman at least once. The analytic data set permitted us to monitor testing over time for the individual woman. The study protocol was reviewed and approved by the Institutional Review Board at the CDC.
Our analysis included women aged 15-60 years. We limited our analysis to include only NAATs for CT and GC because 99.9% of all CT and GC tests performed by this laboratory during the study period were NAATs. In addition, only NAATs with either a positive or a negative test result for women aged 15-60 years were included in this analysis; only 0.9% of tests did not have a positive or negative result. Among women with any CT or GC test, we estimated the proportions with a rectal or pharyngeal test. We defined the "index date" as the date of the first rectal CT and GC test during the study period. We estimated positivity of rectal CT and GC tests on the index date by age, insurance type, US geographic region of residence, STD diagnosis or STD-related symptom based on ICD-9 codes, and provider specialty. On the index date, we also assessed whether genital and pharyngeal testing was performed, and the positivity of these tests. In addition, we estimated the frequency of combinations of positivity of genital, rectal, and pharyngeal CT and GC tests performed on the index date if all anatomic sites were tested (genital CT, rectal CT, pharyngeal CT, genital GC, rectal GC, and pharyngeal GC).
We assessed follow-up testing at any anatomic site of women who were classified into 1 of 4 hierarchical groups based on their test positivity on the index date: (1) a positive rectal CT or GC test; (2) negative rectal CT and GC tests but a positive pharyngeal CT or GC test (if pharyngeal testing was performed on the index date); (3) negative rectal CT and GC tests, negative pharyngeal CT and GC tests or no pharyngeal CT or GC tests, and a positive genital CT or GC test (if genital testing was performed on the index date); (4) negative CT and GC tests at all tested anatomic sites, including women who did not have pharyngeal or genital testing on the index date. To allow at least 12 months of follow-up time, we limited the analysis to women with an index date prior to 1 October 2014. Because falsepositive NAAT results can occur in specimens collected sooner than 3 weeks after completion of therapy [16] , we estimated the proportion of women who had any follow-up test (genital, rectal, or pharyngeal) from day 21 through day 365 after the index test. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, North Carolina). Testing rates and positivity between groups were compared using a χ 2 test and a 2-sided P value <.05 was considered statistically significant.
RESULTS
Of 7.9 million women aged 15-60 years who were tested for CT or GC, 30.0% were aged 15-24 years, 11.8% had Medicaid insurance, 54.2% resided in the South, 0.1% had rectal testing, and 0.5% had pharyngeal testing (Table 1) . Of 5499 women aged 15-60 years who had rectal CT and GC testing, 70.9% were aged 15-34 years, 72.1% resided in the South, and 66.3% received care from an infectious disease specialist (Table 2) . Overall, positivity for rectal CT or GC was 10.8%: 8.0% for CT only, 2.0% for GC only, and 0.8% for both. Rectal CT positivity was significantly (P < .05) higher for women aged 15-24 years than women aged 25-60 years and for women who visited infectious disease specialists or public health clinics than other healthcare providers. Women who were tested more than once for rectal CT or GC were significantly more likely (P < .05) to have a positive test result on the index date than women who were tested only once on the index date. Approximately 80% of women with a rectal CT and GC test on the index date also had genital CT and GC testing and pharyngeal GC testing, while only 40% had pharyngeal CT testing. Of 5499 women who had rectal CT and GC testing, 1865 (33.9%) had CT and GC testing at all 3 anatomical sites (6 tests total). Of these 1865 women with testing at all 3 anatomical sites, 88.4% had 6 negative results, 11.6% had positive rectal or pharyngeal CT or GC tests, and 9.2% had positive rectal CT or GC tests. If only genital testing among these 1865 women had been performed, 103 of 217 women with a positive CT or GC test at the rectal or pharyngeal site (47.5%) would not have been identified as being infected, and 80 of 172 women with a positive rectal CT or GC test (46.5%) would not have been identified. Of 5499 women who had rectal CT and GC testing, 3090 (56.2%) had an index testing date prior to 1 October 2014. Of these 3090 women, the cumulative rates of repeat rectal testing and follow-up testing at any anatomic sites are presented in Figure 2 . The proportion of women who had any follow-up test was significantly higher (P < .05) among women with an infection on the index date than among uninfected women: 19.1% vs 9.2% for follow-up rectal testing within 12 months and 46.3% vs 28.4% for follow-up testing at any anatomic site within 12 months. Among women with a positive rectal CT or GC test on the index test date who had a follow-up test (20.0%), 17.7% had a positive rectal CT or GC test, 5.2% a positive pharyngeal CT or GC test, and 11.7% a positive genital CT or GC test (Table 3) . Among women without any positive test on the index date who had a follow-up test, 8.9% had a positive rectal CT or GC test, 2.2% a positive pharyngeal CT or GC test, and 6.1% a positive genital CT or GC test.
DISCUSSION
We found that a large number of women were tested for genital CT and GC, but <0.1% had rectal testing. This rate was very low given the large proportion of US women who reported ever having anal sex in national surveys. Among women aged 15-60 years who were tested for rectal CT or GC, 10.8% had positive tests; among women aged 15-24 years, 16.5% had positive tests. The high positivity on the index date might indicate that much of the rectal testing is diagnostic, rather than screening of asymptomatic patients who report exposure. A high proportion (46.5%) of women with a positive rectal CT or GC test did not have a positive genital test. Healthcare providers who do not test women at all sites of exposure might miss rectal infections in women.
Our finding of infrequent rectal testing indicate that most women who have anal sex are not being tested for rectal CT or GC. A recent review article described rectal infections in women as the result of autoinoculation from a genital chlamydial or gonococcal infection [17] . But we found that a large number of women had only a rectal infection (46.5%), and these infections would have been undiagnosed and untreated with genital screening alone. Our estimate of the proportion of women with only a rectal infection is higher than in the previous studies that found positivity rates of 5%-29% [8, 9, [17] [18] [19] [20] [21] [22] [23] . In one of these studies, it was found that 59% of women in STD clinics were tested for rectal CT and GC after they reported receptive anal sex and that many rectal infections would be missed with urogenital testing alone [8] . Healthcare providers might consider conducting a comprehensive sexual history that includes questions about anal sex and offer rectal screening to women who report anal sex, a prior STD, or multiple sex partners. While some women might be hesitant to report anal sex [23] , it is important that women be asked about it during the sexual history.
Rectal infections have been found to be associated with an increased risk of HIV infection and anal cancer in women [11, 17, 24] . Rectal chlamydia and gonorrhea can be markers of anal sex, and mathematical models have found that 40% of HIV infections in women are attributable to anal sex [13, 25] . These findings suggest that rectal CT and GC screening may be an important method to identify women who would benefit from HIV preexposure prophylaxis (PrEP) and from the HPV vaccine. PrEP greatly reduces the risk of HIV infection, but few women use PrEP [26] . Rectal chlamydia and gonorrhea can also result in rare but serious health consequences for women including proctitis, disseminated gonococcal infection, and lymphogranuloma venereum [27, 28] . In addition, rectal CT and GC in women can potentially translocate and autoinoculate the vagina and cervix, causing genital infection and the associated serious sequelae [29] . Our study also found that very few women with chlamydia or gonorrhea had a repeat test as recommended. Compared to men with infection who had repeat testing rates of 40.0%, women had repeat testing rates of only 20.0%. Women who had rectal infection also had lower rates of follow-up testing (43.6%) at any anatomic sites than men (56.7%) [30] . The high proportion of women who were reinfected highlights the importance of follow-up testing at all anatomic sites.
Our study had limitations. First, because this laboratory system does not include information on the patient's sexual behavior or information on sex partners, we were unable to estimate the number of women who engaged in anal sex and had rectal testing. Second, because a large proportion of women in our study received healthcare from infectious disease specialists, they might have been at greater risk of chlamydia or gonorrhea. This would result in an overestimate of test positivity. Third, more than half of women with Figure 2 . Cumulative frequency of follow-up testing for chlamydia or gonorrhea at any anatomic site (A) and at rectal site (B) after the index date by initial infection status at the index date (N = 3090). The index date is the date of the first rectal chlamydia and gonorrhea test for each woman during the study period. rectal specimens did not have a diagnostic code recorded and this might have resulted in an underestimate of women who had an STD or STD symptoms when they were tested. Fourth, treatment information was not available in this laboratory system, so we were unable to estimate the proportion of women with positive tests who were appropriately treated. Finally, the population of women with Medicaid might be underrepresented in this database because of the low proportion of women with Medicaid in this database.
We found that only a very small number of rectal CT and GC tests were performed for women. Among women who were tested at the rectal site, positivity was high. Among women who had a positive test on the index date, the follow-up testing rate was low but the positivity rates of the follow-up tests were high. To provide high-quality sexual and reproductive healthcare for women, interventions are needed to ensure that the risks associated with anal sex can be minimized. These interventions include educating women and healthcare providers about risks of anal sex; implementing rectal screening for at-risk women by asking about anal sex when conducting a sexual history; and developing reminder systems to prompt clinicians to perform follow-up testing at all anatomic sites for women who had a positive rectal test.
